-

insitro Appoints Tom Stocky as Vice President of Product

Former Google & Facebook executive to focus on establishing product strategy, planning, and user experience for insitro’s ML-enabled platform, spanning data acquisition, processing, and analysis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, a machine learning-driven drug discovery and development company, today announced that Tom Stocky has been appointed as vice president of product. Mr. Stocky has spent the majority of his career working in technology, including at Facebook, Google, and most recently in a technology-focused role at Denali Therapeutics. In his role at insitro, he will lead product strategy, planning, and user experience for insitro’s data systems and software tools.

“Our aspiration at insitro is to build a machine-learning-enabled approach to discover and advance new therapeutic interventions. Key to that vision is the construction of a platform that continually improves as we accumulate data and use them to empower novel ML methods that help de-risk and accelerate drug discovery,” said Daphne Koller, Ph.D., co-founder and CEO of insitro. “This platform is a new type of data product. To build it, we are planning to leverage the approaches that have allowed tech companies to design ML-enabled internet products that operate seamlessly and scale to hundreds of millions of users and petabytes of data. Tom was the architect and leader of some of these industry-leading products, and we are excited to have him join us to help us bring medicines to patients in need.”

"insitro is unraveling human biology, using machine learning to generate and leverage biological and chemical data that will help create safe and effective new medicines for patients," said Mr. Stocky. “They're bridging the gap between software and biology, not just from a technology perspective, but also in terms of the organization they're building. Bringing together such a diverse team — from bench scientists to data scientists, machine learning engineers to process engineers — insitro has a unique opportunity to transform drug discovery and development. I'm inspired by their mission and approach and feel lucky to join such an incredible team.”

Mr. Stocky has more than 15 years of experience building technology products. During his career, Mr. Stocky was vice president of search at Facebook, where he grew the Facebook Search service to more than 2 billion searches per day across the community's more than 3 trillion posts. He also led teams responsible for profile, entity graph, and language technology. In his prior role at Google, he helped start the developer products team and was part of the founding team for Google App Engine, which laid the foundation for Google's Cloud Platform. More recently, he served as head of learning platform at the Chan Zuckerberg Initiative, where he oversaw the engineering, product, and design teams for their education technology efforts. In his most recent role, he was a technology fellow at Denali Therapeutics, where he helped expand the use of machine learning techniques to support their discovery work and helped further develop their digital strategy for engaging with patients. Mr. Stocky serves on the board of directors of the Banner Alzheimer's Foundation and on the scientific advisory board for Denali Therapeutics. He received an MEng and B.S. in computer science & electrical engineering from MIT and an MBA from MIT Sloan.

About insitro
insitro is a data-driven drug discovery and development company using machine learning and data generation at scale to transform the way that drugs are discovered and delivered to patients. insitro’s approach focuses on the development of predictive machine learning models to be brought to bear on key bottlenecks in pharmaceutical R&D. The company has established enabling collaborations with Gilead in NASH and Bristol Myers Squibb in ALS. insitro is located in South San Francisco, CA and has been supported by top tech, biotech, and crossover investors since formation in 2018. For more information on insitro, please visit the company’s website at www.insitro.com.

Contacts

Media Contact
Dan Budwick
dan@1abmedia.com

Company Contact
queries@insitro.com

insitro


Release Summary
insitro Appoints Tom Stocky as Vice President of Product
Release Versions

Contacts

Media Contact
Dan Budwick
dan@1abmedia.com

Company Contact
queries@insitro.com

More News From insitro

insitro to Present at the 44th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, the AI therapeutics company built on causal biology, today announced that Daphne Koller, Ph.D., founder and CEO, will present a company update, including its AI-enabled discovery engine and therapeutic candidates advancing to the clinic, at the 44th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, at 4:00 p.m. PT in San Francisco. Additional insitro participation at healthcare week events: Longwood Healthcare Leaders’ San Franci...

insitro Validates AI-Enabled POSH Platform in Nature Communications, Bridging Critical Gap in Drug Discovery

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, the AI therapeutics company built on causal biology, today announced the publication of research in Nature Communications validating its POSH (Pooled Optical Screening in Human cells) platform. The study details the development of CellPaint-POSH, a scalable approach that integrates pooled CRISPR screening, high-content imaging, and advanced machine learning to map gene function at scale without relying on predefined biomarkers or human-engi...

insitro Appoints R&D Veteran Stephen Hitchcock and AI Visionary Vijay Pande as Scientific Advisors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, the AI therapeutics company built on causal biology, today announced the appointment of two scientific advisors: Stephen Hitchcock, Ph.D., a preeminent drug development leader and former Chief Scientific Officer of Takeda, and Vijay Pande, Ph.D., co-founder of VZVC and, previously, founder and General Partner of Andreessen Horowitz's Bio + Health fund. Hitchcock and Pande will advise on the continued development and scaling of insitro's AI-...
Back to Newsroom